AAB-001 in Patients With Mild to Moderate Alzheimer's Disease
Alzheimer's Disease
About this trial
This is an interventional treatment trial for Alzheimer's Disease focused on measuring Alzheimer's disease, immunotherapy, beta amyloid
Eligibility Criteria
Inclusion Criteria: Diagnosis of probable AD Age from 50 to 85 years Rosen Modified Hachinski Ischemic score less than or equal to 4 Magnetic resonance imaging (MRI) scan consistent with the diagnosis of AD Fluency in English Stable doses of medications Exclusion Criteria: Significant neurological disease other than AD Major psychiatric disorder Significant systemic illness History of stroke or seizure Weight greater than 120 kg (264 lbs.) History of autoimmune disease Smoking more than 20 cigarettes per day Anticonvulsants, anti-Parkinson's, anticoagulant, or narcotic medications Prior treatment with experimental immunotherapeutics or vaccines for AD Presence of pacemakers or foreign metal objects in the eyes, skin, or body
Sites / Locations
- Cleo Roberts Center for Clinical Research / Sun Health Research Institute
- UC Irvine
- Pharmacology Research Institute
- Pharmacology Research Institute
- UCSD Shiley-Marcos Alzheimer's Disease Research Center
- Memory & Aging Center, UCSF
- Yale University School of Medicine
- Georgetown University Medical Center
- Brain Matters Research, Inc.
- Mayo Clinic - Department of Neurology
- Rush Presbyterian St. Luke's Medical Center
- Department of Neurology - Indiana University Medical Center
- Behavioral Neurology
- University of Michigan Health System, Department of Neurology
- Mayo Clinic Department of Neurology - Alzheimer's Disease Research Center
- The Memory Enhancement Center
- Sergievsky Center, Columbia University
- University of Rochester / Monroe Community Hospital
- Department of Psychiatry and Behavioral Sciences
- Oregon Health and Science University
- University of Pittsburgh
- Memory and Aging Program, Butler Hospital
- University of Texas Southwestern Medical Center
- Baylor College of Medicine
- Clinical Neuroscience Research Associates, Inc.
- University of Washington
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Arm 7
Arm 8
Experimental
Placebo Comparator
Experimental
Placebo Comparator
Experimental
Placebo Comparator
Experimental
Placebo Comparator
0.15 mg/kg active bapineuzumab
0.15 mg/kg placebo
0.5 mg/kg active bapineuzumab
0.5 mg/kg placebo
1.0 mg/kg active bapineuzumab
1.0 mg/kg placebo
2.0 mg/kg active bapineuzumab
2.0 mg/kg placebo